Nursing Elites

1. A client is starting therapy with cisplatin. Which of the following findings should the nurse instruct the client to report?

• A. Tinnitus
• B. Nausea
• C. Constipation
• D. Weight gain

Correct answer: A

Rationale: Tinnitus should be reported by the client as it can be indicative of ototoxicity, an adverse effect associated with cisplatin therapy. Ototoxicity can result in damage to the inner ear structures, leading to hearing problems. Therefore, prompt reporting of tinnitus is essential for early intervention and prevention of potential complications. Nausea, constipation, and weight gain are common side effects of cisplatin but are not typically indicative of serious complications requiring immediate reporting compared to tinnitus.

2. A client is being taught about a new prescription for Celecoxib. Which of the following information should be included in the teaching?

• A. Increases the risk for a myocardial infarction
• B. Decreases the risk of stroke
• C. Inhibits COX-1
• D. Increases platelet aggregation

Correct answer: A

Rationale: The correct answer is A: 'Increases the risk for a myocardial infarction.' Celecoxib, a COX-2 inhibitor, increases the risk for a myocardial infarction due to its effect on suppressing vasodilation, which can lead to this adverse cardiovascular event. Choices B, C, and D are incorrect. Celecoxib does not decrease the risk of stroke, inhibit COX-1, or increase platelet aggregation. It's crucial for the nurse to educate the client about the increased risk for a myocardial infarction when taking Celecoxib and emphasize monitoring for signs of heart issues and the importance of seeking prompt medical attention if symptoms occur.

3. A client is prescribed Lithium. Which of the following laboratory values should be monitored to assess for potential toxicity?

• A. Serum sodium
• B. Serum lithium
• C. Serum potassium
• D. Serum calcium

Correct answer: B

Rationale: When a client is prescribed Lithium, monitoring serum lithium levels is crucial to ensure they remain within the therapeutic range and to assess for potential toxicity. Monitoring serum lithium levels helps prevent adverse effects associated with lithium toxicity, such as nausea, vomiting, diarrhea, tremors, and confusion.

4. A healthcare provider is teaching a client who has a new prescription for Bisacodyl suppositories. Which of the following information should the provider include?

• A. Expect results within 15 to 60 minutes.
• B. Insert the suppository as directed by the healthcare provider.
• C. Keep the suppository at room temperature.
• D. Expect rectal burning.

Correct answer: D

Rationale: When educating a client about Bisacodyl suppositories, it is important to include information about the common side effects. Rectal burning is a frequent side effect that can occur after using Bisacodyl suppositories, so the client should be informed to expect this discomfort. The onset of action for Bisacodyl suppositories is typically within 15 to 60 minutes, so the client should expect results relatively quickly, not in 6 to 12 hours. It is essential to follow the healthcare provider's instructions on how to insert the suppository correctly. Keeping the suppository at room temperature is sufficient; refrigeration is not required. Therefore, option D is the correct choice as it addresses a common side effect and prepares the client for potential discomfort. Options A, B, and C are incorrect as they do not focus on a significant side effect, proper administration, or storage requirements.

5. A client is receiving treatment with bevacizumab. Which of the following findings should the nurse monitor?

• A. Hypertension
• B. Hypokalemia
• C. Hyperglycemia
• D. Hypocalcemia

Correct answer: A

Rationale: Correct Answer: A. Bevacizumab is known to cause hypertension as a common adverse effect. The nurse should closely monitor the client's blood pressure to detect and manage this potential side effect promptly. Choice B, hypokalemia, is not typically associated with bevacizumab treatment. Choice C, hyperglycemia, is not a common adverse effect of bevacizumab. Choice D, hypocalcemia, is not a recognized side effect of bevacizumab.

Similar Questions